— WUSTL Technology 007646
Technology Description
Researchers at Washington University in St. Louis (WUSTL) have developed a novel TRAIL (TNF-related apoptosis inducing ligand)-based anticancer drug platform, designated TR3. TRAIL has potent and specific apoptotic activity against tumor cells. Thus,…
— Technology Description
A team of researchers at Washington University has created a machine learning method to quickly and reliably validate patient contours in digital medical images for radiation therapy and computer aided image analysis.
Currently, automated contouring tools for delineating tu…
— Technology Description
Researchers in Dr. Perry Grigsby’s lab have developed a patented brachytherapy device for outpatient, MRI-guided treatment of gynecological cancers. Gynecological cancers, such as recurrent endometrial and cervical cancers, can be treated with brachytherapy, but requir…
— Background: In the US alone, 154,000 new cases of colorectal cancer (CRC) are diagnosed each year. Unfortunately, a third of those patients will die due to diagnosis at late stages – the 5-year survival rate is 11%, compared to 91% for those who are diagnosed with only localized CRC. A colonos…
— The monoclonal antibodies developed are agaonistic monoclonal antibodies. These antibodies can help in enhancing the immune system by activating dendritic cell subsets. Furthermore, these antibodies are unique, as they can activate Dendritic cells without the need for cross-linking the receptor.
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
